SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Merck KGaA MKKGY OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • DE • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Merck KGaA (MKKGY) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $27.62. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $20.3B, -3%/yr average growth. Net income is $2.5B, growing at -8.8%/yr. Net profit margin is 12.4% (healthy). Gross margin is 56.4% (-5.2 pp trend).

Balance sheet: total debt is $12.0B against $28.6B equity (Debt-to-Equity (D/E) ratio 0.42, conservative). Current ratio is 1.46 (adequate). Debt-to-assets is 23%. Total assets: $52.1B.

Analyst outlook: 2 / 2 analysts rate MKKGY as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 15/100 (Fail), Past 100/100 (Pass), Health 83/100 (Pass), Moat 69/100 (Partial), Future 100/100 (Pass), Income 55/100 (Partial).

MKKGY SharesGrow Score Overview

71/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 75/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 83/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 69/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MKKGY

MKKGY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

MKKGY: -3%/yr revenue is, -8.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

MKKGY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet MKKGY: Debt-to-Equity (D/E) ratio 0.42 (conservative), Current ratio is 1.46 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

MKKGY: Gross margin is 56.4% (-5.2 pp trend), $60B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 69/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 2 analysts rate MKKGY as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

MKKGY: Net profit margin is 12.4%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range23.73-31

Volume8.41K

Avg Volume (30D)133.86K

Market Cap$60.04B

Beta (1Y)0.80

Dividend Yield$0.5004

Share Statistics

EPS (TTM)1.15

Shares Outstanding$2.17B

IPO Date2007-11-16

Employees59,020

CEOBelen Garijo Lopez

Financial Highlights & Ratios

Revenue (TTM)$20.27B

Gross Profit$11.42B

EBITDA$5.71B

Net Income$2.51B

Operating Income$3.9B

Total Cash$2.74B

Total Debt$11.96B

Net Debt$9.22B

Total Assets$52.08B

Price / Earnings (P/E)24

Price / Sales (P/S)2.96

Analyst Forecast

Rating ConsensusBuy

Analysts Covering2

Buy 100% Hold 0% Sell 0%

Company Info

CountryDE

ExchangeOther OTC

CurrencyUSD

ISINUS5893392093

Price Chart

MKKGY

Merck KGaA ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

23.73 52WK RANGE 31.00

People Also View

Fresenius SE & Co. KGaA

Recruit Holdings Co., Ltd.

MERCK Kommanditgesellschaft auf Aktien

Straumann Holding AG

Ono Pharmaceutical Co., Ltd.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message